<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406419</url>
  </required_header>
  <id_info>
    <org_study_id>ACT3985g</org_study_id>
    <secondary_id>WA20494</secondary_id>
    <nct_id>NCT00406419</nct_id>
  </id_info>
  <brief_title>A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)</brief_title>
  <acronym>STAGE</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in&#xD;
      combination with methotrexate in patients with active rheumatoid arthritis who have had an&#xD;
      inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of&#xD;
      intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of&#xD;
      i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg -&#xD;
      25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment&#xD;
      is 1-2 years. Target sample size is 1000.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on analysis of results and consideration of available treatments, the overall benefit to&#xD;
    risk profile of ocrelizumab was not favorable in RA.&#xD;
  </why_stopped>
  <start_date type="Actual">December 27, 2006</start_date>
  <completion_date type="Actual">April 22, 2015</completion_date>
  <primary_completion_date type="Actual">October 6, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From baseline up to 8.5 years</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6) at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28 at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline &lt; -1.2. EULAR Moderate response: DAS28 &gt;3.2 to ≤ 5.1 or a change from Baseline &lt; -0.6 to ≥ -1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Weeks 24, 48</time_frame>
    <description>68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. A negative change indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global VAS at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global VAS at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as &quot;maximum disease activity&quot; (maximum arthritis disease activity). A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Erosion Score at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48</measure>
    <time_frame>Weeks 24, 48</time_frame>
    <description>Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and</measure>
    <time_frame>Week 24, 48</time_frame>
    <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48</measure>
    <time_frame>Baseline, Week 24, 48</time_frame>
    <description>The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1015</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo × 2 IV + MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 200 mg × 2 IV + MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 500 mg × 2 IV + MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate tablet was administered orally at a dose 7.5-25 mg</description>
    <arm_group_label>Ocrelizumab 200 mg × 2 IV + MTX</arm_group_label>
    <arm_group_label>Ocrelizumab 500 mg × 2 IV + MTX</arm_group_label>
    <arm_group_label>Placebo × 2 IV + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Ocrelizumab was administered via IV infusion at a dose specified in arm description</description>
    <arm_group_label>Ocrelizumab 200 mg × 2 IV + MTX</arm_group_label>
    <arm_group_label>Ocrelizumab 500 mg × 2 IV + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to ocrelizumab was administered via IV infusion</description>
    <arm_group_label>Placebo × 2 IV + MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patients, ≥18 years of age&#xD;
&#xD;
          -  Rheumatoid arthritis for ≥ 3 months&#xD;
&#xD;
          -  Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Rheumatic autoimmune disease or inflammatory joint disease, other than RA&#xD;
&#xD;
          -  Prior receipt of any biologic therapy for RA&#xD;
&#xD;
          -  Concurrent treatment with any DMARD (other than methotrexate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trial Information Support Line</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <disposition_first_submitted>June 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 4, 2013</disposition_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-CD20</keyword>
  <keyword>stage</keyword>
  <keyword>CD20</keyword>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo × 2 IV + MTX</title>
          <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
        </group>
        <group group_id="P2">
          <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
        <group group_id="P3">
          <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="344"/>
                <participants group_id="P3" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="344"/>
                <participants group_id="P3" count="347"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="288"/>
                <participants group_id="P3" count="282"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo × 2 IV + MTX</title>
          <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
        </group>
        <group group_id="B2">
          <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
        <group group_id="B3">
          <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="320"/>
            <count group_id="B2" value="343"/>
            <count group_id="B3" value="343"/>
            <count group_id="B4" value="1006"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="11.54"/>
                    <measurement group_id="B2" value="51.8" spread="11.97"/>
                    <measurement group_id="B3" value="50.9" spread="12.23"/>
                    <measurement group_id="B4" value="51.1" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="282"/>
                    <measurement group_id="B4" value="813"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24</title>
        <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24</title>
          <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="30.5" upper_limit="41.0"/>
                    <measurement group_id="O2" value="56.9" lower_limit="51.6" upper_limit="62.1"/>
                    <measurement group_id="O3" value="54.5" lower_limit="49.2" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Weighted difference</param_type>
            <param_value>18.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11</ci_lower_limit>
            <ci_upper_limit>25.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Weighted difference</param_type>
            <param_value>21.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.1</ci_lower_limit>
            <ci_upper_limit>28.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48</title>
        <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
        <time_frame>Week 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48</title>
          <description>ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="22.7" upper_limit="32.5"/>
                    <measurement group_id="O2" value="58.3" lower_limit="53.1" upper_limit="63.5"/>
                    <measurement group_id="O3" value="62.1" lower_limit="57.0" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Weighted difference</param_type>
            <param_value>30.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.7</ci_lower_limit>
            <ci_upper_limit>37.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Weighted difference</param_type>
            <param_value>34.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.4</ci_lower_limit>
            <ci_upper_limit>41.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.</description>
        <time_frame>From baseline up to 8.5 years</time_frame>
        <population>The safety population included all participants who were randomized and received any part of an infusion of study drug and provided at least one assessment of safety.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.</description>
          <population>The safety population included all participants who were randomized and received any part of an infusion of study drug and provided at least one assessment of safety.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4"/>
                    <measurement group_id="O2" value="82.2"/>
                    <measurement group_id="O3" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48</title>
        <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
        <time_frame>Week 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48</title>
          <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.6" upper_limit="8.7"/>
                    <measurement group_id="O3" value="7.3" lower_limit="4.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6) at Weeks 24 and 48</title>
        <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6) at Weeks 24 and 48</title>
          <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.9" upper_limit="7.8"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.0" upper_limit="10.7"/>
                    <measurement group_id="O3" value="10.8" lower_limit="7.5" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.9" upper_limit="7.8"/>
                    <measurement group_id="O2" value="16.0" lower_limit="12.2" upper_limit="19.9"/>
                    <measurement group_id="O3" value="17.5" lower_limit="13.5" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28 at Weeks 24 and 48</title>
        <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 at Weeks 24 and 48</title>
          <description>The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="340"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="340"/>
                    <count group_id="O3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" spread="1.103"/>
                    <measurement group_id="O2" value="6.40" spread="1.143"/>
                    <measurement group_id="O3" value="6.40" spread="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.329"/>
                    <measurement group_id="O2" value="-2.00" spread="1.248"/>
                    <measurement group_id="O3" value="-2.02" spread="1.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="271"/>
                    <count group_id="O3" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.290"/>
                    <measurement group_id="O2" value="-2.42" spread="1.504"/>
                    <measurement group_id="O3" value="-2.68" spread="1.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48</title>
        <description>DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline &lt; -1.2. EULAR Moderate response: DAS28 &gt;3.2 to ≤ 5.1 or a change from Baseline &lt; -0.6 to ≥ -1.2.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48</title>
          <description>DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline &lt; -1.2. EULAR Moderate response: DAS28 &gt;3.2 to ≤ 5.1 or a change from Baseline &lt; -0.6 to ≥ -1.2.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6"/>
                    <measurement group_id="O2" value="68.8"/>
                    <measurement group_id="O3" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="65.9"/>
                    <measurement group_id="O3" value="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48</title>
        <description>ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48</title>
          <description>ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.2" upper_limit="20.4"/>
                    <measurement group_id="O2" value="31.8" lower_limit="26.9" upper_limit="36.7"/>
                    <measurement group_id="O3" value="31.2" lower_limit="26.3" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="9.2" upper_limit="16.5"/>
                    <measurement group_id="O2" value="39.9" lower_limit="34.8" upper_limit="45.1"/>
                    <measurement group_id="O3" value="36.7" lower_limit="31.6" upper_limit="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48</title>
        <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48</title>
          <description>ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.1" upper_limit="8.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="10.6" upper_limit="18.0"/>
                    <measurement group_id="O3" value="12.2" lower_limit="8.8" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="3.8" upper_limit="9.3"/>
                    <measurement group_id="O2" value="20.7" lower_limit="16.4" upper_limit="25.0"/>
                    <measurement group_id="O3" value="22.4" lower_limit="18.0" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48</title>
        <description>66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48</title>
          <description>66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Percentage of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="311"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.20" spread="66.127"/>
                    <measurement group_id="O2" value="-51.82" spread="80.805"/>
                    <measurement group_id="O3" value="-54.76" spread="39.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.39" spread="59.184"/>
                    <measurement group_id="O2" value="-61.36" spread="44.414"/>
                    <measurement group_id="O3" value="-64.22" spread="65.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48</title>
        <description>68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.</description>
        <time_frame>Baseline, Weeks 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48</title>
          <description>68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Tendor joins</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="311"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.97" spread="58.675"/>
                    <measurement group_id="O2" value="-55.11" spread="37.962"/>
                    <measurement group_id="O3" value="-51.07" spread="49.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.91" spread="64.358"/>
                    <measurement group_id="O2" value="-61.51" spread="37.229"/>
                    <measurement group_id="O3" value="-59.55" spread="48.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48</title>
        <description>The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. A negative change indicated improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48</title>
          <description>The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as &quot;no pain&quot; and the right-hand extreme equals 100 mm as &quot;unbearable pain&quot;. A negative change indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="307"/>
                    <count group_id="O3" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.10" spread="109.646"/>
                    <measurement group_id="O2" value="-32.02" spread="88.637"/>
                    <measurement group_id="O3" value="-27.73" spread="139.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="293"/>
                    <count group_id="O3" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="148.933"/>
                    <measurement group_id="O2" value="-38.86" spread="104.267"/>
                    <measurement group_id="O3" value="-32.47" spread="197.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global VAS at Weeks 24 and 48</title>
        <description>The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity).</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global VAS at Weeks 24 and 48</title>
          <description>The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as &quot;maximum disease activity&quot; (maximum arthritis disease activity).</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.23" spread="39.655"/>
                    <measurement group_id="O2" value="-51.44" spread="34.669"/>
                    <measurement group_id="O3" value="-53.02" spread="34.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.60" spread="43.285"/>
                    <measurement group_id="O2" value="-61.29" spread="31.543"/>
                    <measurement group_id="O3" value="-62.10" spread="30.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global VAS at Weeks 24 and 48</title>
        <description>The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as &quot;maximum disease activity&quot; (maximum arthritis disease activity). A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global VAS at Weeks 24 and 48</title>
          <description>The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as &quot;maximum disease activity&quot; (maximum arthritis disease activity). A negative change from Baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.73" spread="74.480"/>
                    <measurement group_id="O2" value="-37.96" spread="83.908"/>
                    <measurement group_id="O3" value="-36.99" spread="79.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="294"/>
                    <count group_id="O3" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.13" spread="100.706"/>
                    <measurement group_id="O2" value="-42.02" spread="103.526"/>
                    <measurement group_id="O3" value="-55.26" spread="37.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48</title>
        <description>The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48</title>
          <description>The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication.</population>
          <units>Milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="311"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.64" spread="116.697"/>
                    <measurement group_id="O2" value="-30.41" spread="109.193"/>
                    <measurement group_id="O3" value="-23.07" spread="109.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.01" spread="190.346"/>
                    <measurement group_id="O2" value="-40.89" spread="90.139"/>
                    <measurement group_id="O3" value="15.14" spread="820.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48</title>
        <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, 'n' signifies the number of partcipants evaluated at a specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48</title>
          <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, 'n' signifies the number of partcipants evaluated at a specified time point.</population>
          <units>Percentage Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.11" spread="48.921"/>
                    <measurement group_id="O2" value="-30.12" spread="86.217"/>
                    <measurement group_id="O3" value="-40.83" spread="38.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.67" spread="57.893"/>
                    <measurement group_id="O2" value="-35.47" spread="78.670"/>
                    <measurement group_id="O3" value="-45.63" spread="39.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48</title>
        <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, 'n' signifies the number of participants evaluated at a specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48</title>
          <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, 'n' signifies the number of participants evaluated at a specified time point.</population>
          <units>Percentage Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="311"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="311"/>
                    <count group_id="O3" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="66.453"/>
                    <measurement group_id="O2" value="-20.10" spread="90.059"/>
                    <measurement group_id="O3" value="-29.98" spread="57.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="57.893"/>
                    <measurement group_id="O2" value="-27.24" spread="147.973"/>
                    <measurement group_id="O3" value="-41.19" spread="55.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48</title>
        <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>mITT population. Number of participants analysed signifies participants who were evaluated for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48</title>
          <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>mITT population. Number of participants analysed signifies participants who were evaluated for the endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.58" spread="51.106"/>
                    <measurement group_id="O2" value="31.45" spread="51.323"/>
                    <measurement group_id="O3" value="31.99" spread="49.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="2.842"/>
                    <measurement group_id="O2" value="0.34" spread="2.424"/>
                    <measurement group_id="O3" value="-0.03" spread="2.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="5.293"/>
                    <measurement group_id="O2" value="0.26" spread="2.791"/>
                    <measurement group_id="O3" value="-0.03" spread="2.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Erosion Score at Weeks 24 and 48</title>
        <description>The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>mITT population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies participants who were evaluated for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Erosion Score at Weeks 24 and 48</title>
          <description>The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.</description>
          <population>mITT population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies participants who were evaluated for the endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.10" spread="27.256"/>
                    <measurement group_id="O2" value="16.22" spread="27.875"/>
                    <measurement group_id="O3" value="16.24" spread="26.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.778"/>
                    <measurement group_id="O2" value="0.18" spread="1.487"/>
                    <measurement group_id="O3" value="0.04" spread="1.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="3.238"/>
                    <measurement group_id="O2" value="0.08" spread="1.690"/>
                    <measurement group_id="O3" value="-0.08" spread="1.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48</title>
        <description>The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>mITT population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies participants who were evaluated for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48</title>
          <description>The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.</description>
          <population>mITT population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies participants who were evaluated for the endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.47" spread="25.990"/>
                    <measurement group_id="O2" value="15.22" spread="25.012"/>
                    <measurement group_id="O3" value="15.75" spread="25.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.654"/>
                    <measurement group_id="O2" value="0.16" spread="1.655"/>
                    <measurement group_id="O3" value="-0.07" spread="1.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                    <count group_id="O2" value="308"/>
                    <count group_id="O3" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="2.777"/>
                    <measurement group_id="O2" value="0.18" spread="1.471"/>
                    <measurement group_id="O3" value="0.05" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48</title>
        <description>Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.</description>
        <time_frame>Weeks 24, 48</time_frame>
        <population>The modified Intent-to-Treat (mITT) population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies subjects who were evaluated for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48</title>
          <description>Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.</description>
          <population>The modified Intent-to-Treat (mITT) population included all participants who were in the ITT analysis set and had both baseline radiograph and at least one post-baseline radiograph for campaign 1. Here, the number of participants analysed signifies subjects who were evaluated for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="41.9" upper_limit="53.1"/>
                    <measurement group_id="O2" value="58.7" lower_limit="53.3" upper_limit="64.1"/>
                    <measurement group_id="O3" value="65.3" lower_limit="60.2" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" lower_limit="32.3" upper_limit="43.1"/>
                    <measurement group_id="O2" value="58.7" lower_limit="53.3" upper_limit="64.1"/>
                    <measurement group_id="O3" value="60.8" lower_limit="55.5" upper_limit="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48</title>
        <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>mITT population. Number of participants analysed signifies participants who were evaluated for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48</title>
          <description>mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>mITT population. Number of participants analysed signifies participants who were evaluated for the endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="8.2" upper_limit="15.4"/>
                    <measurement group_id="O2" value="22.7" lower_limit="18.1" upper_limit="27.2"/>
                    <measurement group_id="O3" value="29.8" lower_limit="24.8" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and</title>
        <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
        <time_frame>Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and</title>
          <description>HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="36.9" upper_limit="47.7"/>
                    <measurement group_id="O2" value="59.8" lower_limit="54.6" upper_limit="65.0"/>
                    <measurement group_id="O3" value="66.5" lower_limit="61.5" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="29.6" upper_limit="40.0"/>
                    <measurement group_id="O2" value="58.9" lower_limit="53.7" upper_limit="64.1"/>
                    <measurement group_id="O3" value="65.9" lower_limit="60.9" upper_limit="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48</title>
        <description>The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48</title>
          <description>The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Mental Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="334"/>
                    <count group_id="O3" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.54" spread="12.282"/>
                    <measurement group_id="O2" value="39.99" spread="11.863"/>
                    <measurement group_id="O3" value="40.48" spread="12.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mental Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="10.886"/>
                    <measurement group_id="O2" value="6.11" spread="10.082"/>
                    <measurement group_id="O3" value="5.80" spread="11.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48: Mental Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="290"/>
                    <count group_id="O3" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="10.326"/>
                    <measurement group_id="O2" value="6.36" spread="10.212"/>
                    <measurement group_id="O3" value="6.43" spread="11.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="334"/>
                    <count group_id="O3" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.86" spread="7.387"/>
                    <measurement group_id="O2" value="32.24" spread="7.401"/>
                    <measurement group_id="O3" value="31.58" spread="8.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Physical Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="8.421"/>
                    <measurement group_id="O2" value="6.73" spread="8.385"/>
                    <measurement group_id="O3" value="7.71" spread="7.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48: Physical Component Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="290"/>
                    <count group_id="O3" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="8.373"/>
                    <measurement group_id="O2" value="8.38" spread="8.347"/>
                    <measurement group_id="O3" value="9.15" spread="8.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48</title>
        <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48</title>
          <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="340"/>
                <count group_id="O3" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="317"/>
                    <count group_id="O2" value="340"/>
                    <count group_id="O3" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.25" spread="10.821"/>
                    <measurement group_id="O2" value="26.87" spread="10.920"/>
                    <measurement group_id="O3" value="26.57" spread="11.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="309"/>
                    <count group_id="O3" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="9.864"/>
                    <measurement group_id="O2" value="7.18" spread="9.755"/>
                    <measurement group_id="O3" value="7.07" spread="10.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.39" spread="10.054"/>
                    <measurement group_id="O2" value="8.01" spread="10.132"/>
                    <measurement group_id="O3" value="8.41" spread="10.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48</title>
        <description>The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.</description>
        <time_frame>Baseline, Week 24, 48</time_frame>
        <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo × 2 IV + MTX</title>
            <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
            <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48</title>
          <description>The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.</description>
          <population>ITT population included all randomised participants who had received any part of an infusion of study medication. Here, the number of participants analysed signifies participants evaluated for this endpoint.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="340"/>
                <count group_id="O3" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: average pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="340"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="2.011"/>
                    <measurement group_id="O2" value="6.28" spread="2.077"/>
                    <measurement group_id="O3" value="6.42" spread="2.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: pain right now</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="340"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="2.398"/>
                    <measurement group_id="O2" value="5.75" spread="2.495"/>
                    <measurement group_id="O3" value="5.82" spread="2.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: average pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="304"/>
                    <count group_id="O3" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="2.441"/>
                    <measurement group_id="O2" value="-2.45" spread="2.299"/>
                    <measurement group_id="O3" value="-2.48" spread="2.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: pain right now</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="2.775"/>
                    <measurement group_id="O2" value="-2.32" spread="2.659"/>
                    <measurement group_id="O3" value="-2.24" spread="2.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48: average pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="273"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="2.619"/>
                    <measurement group_id="O2" value="-2.92" spread="2.442"/>
                    <measurement group_id="O3" value="-3.06" spread="2.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48: pain right now</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="2.795"/>
                    <measurement group_id="O2" value="-2.66" spread="2.676"/>
                    <measurement group_id="O3" value="-2.92" spread="2.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 33 months.</time_frame>
      <desc>All patients that received any part of an infusion of study drug and provided at least one assessment of safety were included in the safety population. In patients who had received the incorrect therapy from that intended were summarized in the group according to the highest dose of double-blind therapy they actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo × 2 IV + MTX</title>
          <description>Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.</description>
        </group>
        <group group_id="E2">
          <title>Ocrelizumab 200 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
        <group group_id="E3">
          <title>Ocrelizumab 500 mg × 2 IV + MTX</title>
          <description>Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Otosalpingitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cellulitis gangrenous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Mycobacterium kansasii infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Purulent synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myxoid liposarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urogenital fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rheumatoid vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="273" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="343"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="318"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="343"/>
                <counts group_id="E3" events="29" subjects_affected="23" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="318"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="343"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="318"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="343"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="343"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="343"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="39" subjects_at_risk="318"/>
                <counts group_id="E2" events="59" subjects_affected="43" subjects_at_risk="343"/>
                <counts group_id="E3" events="47" subjects_affected="40" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="318"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="343"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="318"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="343"/>
                <counts group_id="E3" events="35" subjects_affected="29" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="318"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="343"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="60" subjects_affected="45" subjects_at_risk="318"/>
                <counts group_id="E2" events="56" subjects_affected="43" subjects_at_risk="343"/>
                <counts group_id="E3" events="77" subjects_affected="51" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="318"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="343"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="318"/>
                <counts group_id="E2" events="48" subjects_affected="33" subjects_at_risk="343"/>
                <counts group_id="E3" events="35" subjects_affected="28" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="130" subjects_affected="64" subjects_at_risk="318"/>
                <counts group_id="E2" events="130" subjects_affected="79" subjects_at_risk="343"/>
                <counts group_id="E3" events="157" subjects_affected="85" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="67" subjects_affected="40" subjects_at_risk="318"/>
                <counts group_id="E2" events="49" subjects_affected="38" subjects_at_risk="343"/>
                <counts group_id="E3" events="69" subjects_affected="48" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="136" subjects_affected="62" subjects_at_risk="318"/>
                <counts group_id="E2" events="164" subjects_affected="89" subjects_at_risk="343"/>
                <counts group_id="E3" events="168" subjects_affected="96" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="318"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="343"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="318"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="343"/>
                <counts group_id="E3" events="38" subjects_affected="32" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="318"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="318"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="343"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="318"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="343"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="318"/>
                <counts group_id="E2" events="43" subjects_affected="42" subjects_at_risk="343"/>
                <counts group_id="E3" events="45" subjects_affected="37" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>F. Hoffmann-La Roche Ltd</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

